SCHEMBL1408810

SCHEMBL1408810

CCOC(=O)C(=CCC(C)C)C(=O)OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.50
GLO1 Q04760 1/20 0.50
ALDH1A1 P00352 5/20 0.44
CYP2D6 P10635 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
MAPT P10636 4/20 0.43
LMNA P02545 4/20 0.43
S1PR4 O95977 1/20 0.43
S1PR1 P21453 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
DHODH Q02127 2/20 0.39
GAA P10253 4/20 0.37
TDP1 Q9NUW8 1/20 0.37
PLIN1 O60240 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5085513 0.90 NPSR1 (0.46) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL11719302 0.90 GLO1 (0.60) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL5085510 0.90 NPSR1 (0.46) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL11719294 0.90 GLO1 (0.60) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL15913275 0.84 HCAR2 (0.37) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL15913737 0.83 TSHR (0.50) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL1939600 0.82 NPSR1 (0.58) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL28582961 0.82 CYP2D6 (0.45) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL15913491 0.81 ATM (0.46) NPSR1ALDH1A1SMN1; SMN2MAPTMAPK1
SCHEMBL12553979 0.80 NPSR1 (0.38) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3645625-B1 HIGH STIFFNESS POLYPROPYLENE IMPACT COPOLYMER EXXONMOBIL CHEMICAL PATENTS INC (US) 2024-03-27 EP disclosed
US-11732067-B2 High stiffness polypropylene impact copolymer EXXONMOBIL CHEMICAL PATENTS INC. (US) 2023-08-22 US disclosed
WO-2023122778-A1 PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2023-06-29 WO disclosed
EP-2876118-B1 METHOD FOR PRODUCING SOLID CATALYST COMPONENT FOR USE IN POLYMERIZATION OF OLEFIN, CATALYST FOR USE IN POLYMERIZATION OF OLEFIN, AND METHOD FOR PRODUCING OLEFIN POLYMER TOHO TITANIUM CO LTD (JP) 2022-04-06 EP disclosed
WO-2020183376-A1 GREENER AND ECONOMIC PROCESS FOR PREPARATION OF PREGABALIN HIKAL LIMITED (IN) 2020-09-17 WO disclosed
US-20200140584-A1 High Stiffness Polypropylene Impact Copolymer EXXONMOBIL CHEMICAL PATENTS INC (US) 2020-05-07 US disclosed
EP-3645586-A1 METHOD FOR PRODUCING SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION, CATALYST FOR OLEFIN POLYMERIZATION AND A PROCESS FOR PROPYLENE POLYMERIZATION Toho Titanium Co., Ltd. (JP) 2020-05-06 EP disclosed
EP-3645625-A1 HIGH STIFFNESS POLYPROPYLENE IMPACT COPOLYMER ExxonMobil Chemical Patents Inc. (US) 2020-05-06 EP disclosed
US-10246530-B2 Method for producing solid catalyst component for olefin polymerization, catalyst for olefin polymerization and a process for propylene polymerization TOHO TITANIUM CO., LTD. (JP) 2019-04-02 US disclosed
WO-2019005261-A1 HIGH STIFFNESS POLYPROPYLENE IMPACT COPOLYMER EXXONMOBIL CHEMICAL PATENTS INC. (US) 2019-01-03 WO disclosed
WO-2008062460-A3 CRYSTALLINE FORMS OF PREGABALIN CADILA HEALTHCARE LTD (IN) 2009-01-15 WO disclosed
WO-2009004643-A2 AN IMPROVED PROCESS FOR PREPARATION OF (S)-PREGABALIN AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2009-01-08 WO disclosed
WO-2009001372-A2 A NOVEL PROCESS FOR THE PREPARATION OF PREGABALIN SATYANARAYANA REDDY MANNE (IN) 2008-12-31 WO disclosed
WO-2009001372-A2 A NOVEL PROCESS FOR THE PREPARATION OF PREGABALIN SATYANARAYANA REDDY MANNE (IN) 2008-12-31 WO disclosed
WO-2008062460-A2 CRYSTALLINE FORMS OF PREGABALIN CADILA HEALTHCARE LIMITED (IN) 2008-05-29 WO disclosed
WO-2008062460-A2 CRYSTALLINE FORMS OF PREGABALIN CADILA HEALTHCARE LIMITED (IN) 2008-05-29 WO disclosed
WO-2008062460-A2 CRYSTALLINE FORMS OF PREGABALIN CADILA HEALTHCARE LIMITED (IN) 2008-05-29 WO disclosed
WO-2007127309-A2 PROCESSES FOR THE SYNTHESIS OF 3-ISOBUTYLGLUTARIC ACID TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-11-08 WO disclosed
US-20070259917-A1 Processes for the synthesis of 3-isobutylglutaric acid TEVA PHARMACEUTICALS USA, INC. 2007-11-08 US disclosed
US-20070259917-A1 Processes for the synthesis of 3-isobutylglutaric acid TEVA PHARMACEUTICALS USA, INC. 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259917-A1 Processes for the synthesis of 3-isobutylglutaric acid OGDH, GLUL, PGD NPSR1 2691/4885GLO1 69/4885ALDH1A1 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.